Evaluate’s latest analysis forecasts an $82 billion increase in major product revenues in 2025 – the largest annual growth ...

Uterus was term size, relaxed, with cephalic presentation, left occipito anterior (LOA) position, liquor clinically adequate, vertex 5/5 and fetal heart rate ... Both mother and baby were healthy and ...

Analyst Salveen Richter of Goldman Sachs maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), reducing the price target ...

Vertex's Journavx got FDA approval for acute pain but faces adoption challenges. Click here to read more about VRTX stock and ...

So is this biotech stock a no-brainer buy? I think so. Keith Speights has positions in Vertex Pharmaceuticals. The Motley Fool has positions in and recommends Vertex Pharmaceuticals. The Motley ...

That's why, following this recent FDA approval, Vertex stock makes a no-brainer biotech stock to buy and hold for the long term. Adria Cimino has positions in Vertex Pharmaceuticals. The Motley ...

Analyst is bullish on Vertex Pharmaceuticals, citing FDA approval for JOURNAVX and strong earnings growth potential in 2025.

Scotiabank raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $450 from $433 and keeps a Sector Perform rating on the shares. The company had a strong Q4, with revenue beating ...

The episode highlighted the precarious position of Medicaid programs ... UnitedHealthcare likely to cover Vertex’s pain drug Vertex Pharmaceuticals received FDA approval for a new non-opioid ...

The stock remains a no-brainer pick for pharmaceutical investors. Keith Speights (Vertex Pharmaceuticals): Around 109,000 people have cystic fibrosis (CF). Only one company markets therapies that ...

HOUSTON, January 22, 2025--(BUSINESS WIRE)--Vertex Energy, Inc. ("Vertex" or the "Company"), a leading specialty refiner and marketer of high-quality refined products, together with its affiliates ...